In a phase III, randomized, double-blind trial (IMspire150), Gutzmer et al. evaluated the safety and efficacy of the combination of ICIs (atezolizumab) with BRAF plus MEK inhibitors (vemurafenib-plus-cobimetinib) in patients with advanced BRAFV600 mutation-positive melanoma [9]. Here, MAP2K7 is linked to melanoma.